Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Growth Metrics

Ratios

Nu-Med Plus (NUMD) Long-Term Debt Issuances (2020 - 2025)

Nu-Med Plus' Long-Term Debt Issuances history spans 3 years, with the latest figure at $9384.0 for Q2 2020.

On a quarterly basis, Long-Term Debt Issuances changed N/A to $9384.0 in Q2 2020 year-over-year; TTM through Mar 2021 was $9384.0, a N/A change, with the full-year FY2025 number at $46267.0, changed N/A from a year prior.
Long-Term Debt Issuances hit $9384.0 in Q2 2020 for Nu-Med Plus, down from $40000.0 in the prior quarter.
Over the last five years, Long-Term Debt Issuances for NUMD hit a ceiling of $9384.0 in Q2 2020 and a floor of $9384.0 in Q2 2020.